Skip to content

Syndex Bio

5 viewers · 30d

Total raised

$15.5M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $15.5M
ROUNDS
1
INVESTORS
12
FOUNDED
2022
HQ
Santa Monica, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
5

AI overview

Updated

Syndex Bio is a pioneering biotechnology company dedicated to revolutionizing the pace and depth of biological discovery through the application of advanced technologies. Established in 2022 and located in Cambridge, UK, the company focuses on creating innovative tools designed to enhance research capabilities across various fields in biology and medicine.

What sets it apart

Syndex Bio stands out by integrating molecular technologies with artificial intelligence, enabling researchers to achieve insights faster than traditional methods.

Funding history

1 round
EquityFeb 27, 2025
Form D
+$15.5M$15.5M total

Latest SEC filings

via EDGAR · CIK 0002060901
Form D · Feb 27, 2025View on EDGAR

Products

1 tracked

Syndex AI Platform

Research Platform

The Syndex AI Platform is a comprehensive solution that merges molecular technologies, advanced instrumentation, and artificial intelligence to facilitate the analysis of biological samples. It designed to streamline the research workflow, allowing for more efficient data processing and deeper insights.

  • Integration of molecular analysis techniques with AI
  • Accelerated data processing for timely results
  • User-friendly interface for researchers

Links

WebsiteSEC EDGAR filings